For research use only. Not for therapeutic Use.
CB2R PAM is an orally active cannabinoid type-2 receptors (CB2Rs) positive allosteric modulator. CB2R PAM displays antinociceptive activity in vivo in an experimental mouse model of neuropathic pain[1].
CB2R PAM (100 nM) significantly enhances the ability of CP55940 and 2-AG, but not of AEA, to stimulate [35S]GTPγS binding to CB2Rs[1].
CB2R PAM (1-20 mg/kg; p.o.) displays antinociceptive activity[1].
| Catalog Number | I026676 |
| CAS Number | 2244579-87-9 |
| Synonyms | N-[5-bromo-1-[(4-fluorophenyl)methyl]-4-methyl-2-oxopyridin-3-yl]cycloheptanecarboxamide |
| Molecular Formula | C21H24BrFN2O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C21H24BrFN2O2/c1-14-18(22)13-25(12-15-8-10-17(23)11-9-15)21(27)19(14)24-20(26)16-6-4-2-3-5-7-16/h8-11,13,16H,2-7,12H2,1H3,(H,24,26) |
| InChIKey | NSGDYZCDUPSTQT-UHFFFAOYSA-N |
| SMILES | CC1=C(C(=O)N(C=C1Br)CC2=CC=C(C=C2)F)NC(=O)C3CCCCCC3 |
| Reference | [1]. Gado F, et al. Identification of the First Synthetic Allosteric Modulator of the CB2 Receptors and Evidence of Its Efficacy for Neuropathic Pain Relief. J Med Chem. 2019;62(1):276-287. |
